Pomalidomide

Multiple Myeloma

Pomalidomide is used in combination with the medication dexamethasone to treat multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. It is specifically indicated for adults who have already received at least two prior therapies, including lenalidomide and a proteasome inhibitor. It is used when the cancer has progressed during treatment or within 60 days of completing the previous therapy.

Kaposi Sarcoma

This medication is also used to treat Kaposi sarcoma (KS), a cancer that causes lesions to grow in the skin, mucous membranes, or internal organs. It is approved for use in two specific groups:

• AIDS-related Kaposi sarcoma: For patients whose condition has not responded to highly active antiretroviral therapy (HAART).
• HIV-negative Kaposi sarcoma: For patients who do not have HIV but require systemic treatment for the disease.

Pomalidomide is often reserved for cases where the disease is advanced or has become resistant to other standard treatment options.

Mechanism of Action

Pomalidomide belongs to a class of drugs known as immunomodulatory agents. It is designed to treat certain types of cancer, such as multiple myeloma and Kaposi sarcoma, by affecting the body's immune response and directly attacking cancer cells.

How it Affects Cancer Cells

Pomalidomide works in several ways to control the spread of cancer:

• Immune System Activation: It stimulates the immune system, specifically increasing the activity of T cells and natural killer cells. These cells are responsible for identifying and destroying abnormal or cancerous cells in the body.
• Direct Growth Inhibition: The medication can directly stop the growth of cancer cells and trigger a process called apoptosis, which is programmed cell death.
• Anti-Angiogenesis: It may help prevent the formation of new blood vessels that tumors need to grow and survive.
• Reducing Inflammation: Pomalidomide blocks the production of certain chemicals in the body, such as tumor necrosis factor-alpha (TNF-alpha), which are involved in inflammation and the growth of certain cancers.

While the exact way pomalidomide works for all conditions is not fully understood, these combined actions help to slow the progression of the disease.

Common Side Effects

Commonly reported side effects of pomalidomide include:

• Fatigue and weakness
• Constipation, diarrhea, or nausea
• Loss of appetite
• Back pain, joint pain, or muscle spasms
• Shortness of breath and cough
• Dizziness
• Fever
• Rash
• Numbness, tingling, or burning sensations in the hands or feet

Serious Side Effects

Pomalidomide can cause serious health problems. Contact a healthcare provider immediately if you experience:

• Low blood cell counts: Decreased white blood cells can increase the risk of serious infections. Low red blood cells (anemia) can cause shortness of breath and tiredness. Low platelets can lead to unusual bruising or bleeding.
• Blood clots: Symptoms may include chest pain, shortness of breath, or swelling and pain in the arms or legs. This includes risks of heart attack and stroke.
• Liver toxicity: Signs include yellowing of the skin or eyes, dark urine, and upper stomach pain.
• Severe skin reactions: This includes rare but life-threatening conditions that cause skin peeling, blistering, or painful rashes.
• Tumor lysis syndrome: This is caused by the rapid breakdown of cancer cells and may cause kidney failure or irregular heartbeats.
• Severe allergic reactions: Symptoms include swelling of the face, lips, or throat, and difficulty breathing.

Boxed Warnings

Embryo-Fetal Toxicity: Pomalidomide is a thalidomide analogue that can cause severe, life-threatening birth defects or fetal death. It must not be used during pregnancy. To prevent fetal exposure, the drug is only available through a restricted distribution program called the Pomalidomide REMS program. Females of reproductive potential must use two forms of effective contraception and undergo regular pregnancy testing. Males must use a latex or synthetic condom during sexual contact with females of reproductive potential, even if they have had a successful vasectomy.

Venous and Arterial Thromboembolism: Patients treated with pomalidomide have a significantly increased risk of deep vein thrombosis, pulmonary embolism, myocardial infarction (heart attack), and stroke. Prophylactic antithrombotic treatment is generally recommended based on an assessment of the patient's underlying risk factors.

Hematologic and Hepatic Risks

Hematologic Toxicity: Neutropenia is the most common severe adverse reaction associated with this medication. Anemia and thrombocytopenia (low platelet counts) also occur frequently. Complete blood counts should be monitored weekly for the first eight weeks of treatment and monthly thereafter.

Hepatotoxicity: Hepatic failure, including fatal cases, has been reported. Liver function tests should be monitored monthly to detect potential damage early.

Other Serious Precautions

• Severe Cutaneous Reactions: Life-threatening skin reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported. Treatment should be discontinued if a severe rash occurs.
• Hypersensitivity: Patients with a history of hypersensitivity to thalidomide or lenalidomide may be at higher risk for allergic reactions and should be monitored closely.
• Tumor Lysis Syndrome: This condition may occur in patients with a high tumor burden. Monitoring and appropriate prophylaxis are recommended for at-risk patients.
• Second Primary Malignancies: There is an increased risk of developing new types of cancer, such as acute myelogenous leukemia, in patients receiving immunomodulatory treatments like pomalidomide.
• Dizziness and Confusion: Patients may experience neurological effects including dizziness and confusional states. Caution is advised when performing tasks that require mental alertness.

Pregnancy Risks

Pomalidomide is known to cause severe, life-threatening birth defects or the death of an unborn baby if taken during pregnancy. Because it is chemically related to thalidomide, even a single dose taken by a pregnant person can lead to permanent damage to the fetus.

Due to these risks, the medication is only available through a restricted distribution program. Patients must follow strict requirements, which include:

• Using two forms of effective birth control simultaneously.
• Undergoing regular pregnancy tests before and during treatment.
• Agreeing not to donate blood or sperm during treatment and for a specific period afterward.

Male patients must use a condom during sexual contact with females who can become pregnant, as the drug is present in semen and could harm a developing fetus.

Breastfeeding Considerations

It is not known whether pomalidomide passes into human breast milk. However, because of the risk of serious side effects in a nursing infant, healthcare providers generally advise against breastfeeding while taking this medication.

Dosage Forms

Pomalidomide is available as an oral capsule. It is intended to be swallowed whole and should not be broken, chewed, or opened.

This medication is only available through a restricted distribution program. Because the drug can be absorbed through the skin or lungs, individuals who are pregnant or may become pregnant should not handle the capsules or the medication inside them.

FDA Approval and Indications

Pomalidomide was initially approved by the FDA for the treatment of patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and whose disease progressed on or within 60 days of completion of the last therapy. In 2020, the FDA granted accelerated approval for pomalidomide to treat AIDS-related Kaposi sarcoma that has become resistant to highly active antiretroviral therapy (HAART), as well as Kaposi sarcoma in patients who are HIV-negative.

Boxed Warnings

The FDA has issued boxed warnings for pomalidomide due to the following serious risks:

• Embryo-Fetal Toxicity: Pomalidomide is an analogue of thalidomide and can cause severe, life-threatening birth defects or embryo-fetal death. It is strictly contraindicated during pregnancy.
• Venous Thromboembolism: Patients treated with pomalidomide have a significantly increased risk of developing deep vein thrombosis (DVT) and pulmonary embolism (PE). Prophylactic antithrombotic treatment is typically recommended for patients taking this medication.

REMS Program

Because of the risk of embryo-fetal toxicity, pomalidomide is available only through a restricted distribution program called the Pomalyst REMS program. To prescribe, dispense, or receive this medication, healthcare providers, pharmacies, and patients must be enrolled in and comply with the program's requirements. These requirements include mandatory pregnancy testing for females of reproductive potential and strict adherence to contraception methods for both men and women.

Factors Influencing Cost

Pomalidomide is a specialty medication, and its price can vary based on several factors:

• Insurance Coverage: Most insurance plans and Medicare Part D cover this medication, but it is often placed in a high-tier category, which may require significant coinsurance or co-payments.
• Pharmacy Requirements: Due to safety regulations (REMS program), pomalidomide must be obtained through certified specialty pharmacies, which may have different pricing structures than retail pharmacies.
• Generic Availability: The FDA has approved generic versions of pomalidomide, which may be more affordable than the brand-name version depending on your insurance formulary.

Financial Assistance Options

Because the cost of treatment can be high, several resources may help manage expenses:

• Manufacturer Support: The drug manufacturer often provides co-pay cards for patients with commercial insurance or patient assistance programs for those who are uninsured.
• Non-profit Grants: Some charitable organizations offer financial aid to help patients cover the costs of oncology medications.